Please login to the form below
rocapuldencel-T
This page shows the latest rocapuldencel-T news and features for those working in and with pharma, biotech and healthcare.
Argos hit as kidney cancer immunotherapy fails phase III trial
Argos Therapeutics' hopes of bringing lead cancer immunotherapy rocapuldencel-T to market anytime soon have been dashed after it flunked a pivotal phase III trial. ... Rocapuldencel-T, a personalised immunotherapy that uses individual patients' tumour
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Senior Medical Writer
-
Salary is DOE
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Sudler London - Senior Medical Writer
-
Competitive
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Sudler London - Account Director
-
Competitive
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Account Director or Senior Account Director
-
Salary TBC
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
-
Associate Scientific Director
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Senior Medical Writer, MedComms Agency
-
Salary TBC
Subscribe to our email news alerts
- Tox trouble stalls Sosei/Allergan Alzheimer’s drug
- London cancer hub launched by Cancer Research UK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Making a Difference - The Future of Pharma
- AZ prepares to file COPD triple, taking on rival GSK
- Controversy grows around GP at Hand service after minister’s endorsement
PMHub
Just::Health Communications
Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
